Bradley Foster & Sargent Inc. CT Has $51.47 Million Stake in Boston Scientific Co. (NYSE:BSX)

Bradley Foster & Sargent Inc. CT reduced its stake in shares of Boston Scientific Co. (NYSE:BSX) by 0.6% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 668,396 shares of the medical equipment provider’s stock after selling 4,234 shares during the quarter. Bradley Foster & Sargent Inc. CT’s holdings in Boston Scientific were worth $51,473,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. CVA Family Office LLC raised its holdings in Boston Scientific by 7.4% during the 2nd quarter. CVA Family Office LLC now owns 1,909 shares of the medical equipment provider’s stock worth $147,000 after purchasing an additional 131 shares during the last quarter. International Assets Investment Management LLC raised its holdings in Boston Scientific by 0.6% during the 2nd quarter. International Assets Investment Management LLC now owns 22,596 shares of the medical equipment provider’s stock worth $1,740,000 after purchasing an additional 139 shares during the last quarter. ST Germain D J Co. Inc. grew its position in shares of Boston Scientific by 8.0% during the 2nd quarter. ST Germain D J Co. Inc. now owns 1,923 shares of the medical equipment provider’s stock worth $148,000 after buying an additional 143 shares during the period. Pinnacle Associates Ltd. grew its position in shares of Boston Scientific by 2.0% during the 1st quarter. Pinnacle Associates Ltd. now owns 7,478 shares of the medical equipment provider’s stock worth $512,000 after buying an additional 148 shares during the period. Finally, Transcend Capital Advisors LLC grew its position in shares of Boston Scientific by 2.2% during the 2nd quarter. Transcend Capital Advisors LLC now owns 6,773 shares of the medical equipment provider’s stock worth $522,000 after buying an additional 148 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on BSX. Truist Financial boosted their target price on Boston Scientific from $86.00 to $90.00 and gave the stock a “buy” rating in a research report on Tuesday, July 16th. Barclays boosted their target price on Boston Scientific from $78.00 to $86.00 and gave the stock an “overweight” rating in a research report on Thursday, August 22nd. Royal Bank of Canada restated an “outperform” rating and set a $85.00 target price on shares of Boston Scientific in a research report on Thursday, July 25th. The Goldman Sachs Group initiated coverage on Boston Scientific in a research report on Thursday, May 30th. They set a “buy” rating and a $90.00 target price for the company. Finally, Argus boosted their price objective on Boston Scientific from $80.00 to $95.00 and gave the company a “buy” rating in a research report on Tuesday, May 28th. Three investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Boston Scientific has a consensus rating of “Moderate Buy” and a consensus price target of $85.38.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the company’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $74.12, for a total value of $517,579.96. Following the transaction, the executive vice president now directly owns 40,188 shares of the company’s stock, valued at approximately $2,978,734.56. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold a total of 20,949 shares of company stock valued at $1,627,877 in the last ninety days. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Stock Down 1.2 %

BSX opened at $82.52 on Wednesday. Boston Scientific Co. has a 1-year low of $48.35 and a 1-year high of $84.11. The stock’s fifty day simple moving average is $78.35 and its 200 day simple moving average is $74.39. The company has a current ratio of 1.61, a quick ratio of 1.14 and a debt-to-equity ratio of 0.44. The stock has a market cap of $121.06 billion, a PE ratio of 69.34, a price-to-earnings-growth ratio of 2.75 and a beta of 0.79.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, July 24th. The medical equipment provider reported $0.62 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.04. Boston Scientific had a return on equity of 16.59% and a net margin of 12.00%. The business had revenue of $4.12 billion for the quarter, compared to analysts’ expectations of $4.02 billion. During the same quarter in the prior year, the business earned $0.53 EPS. The firm’s revenue for the quarter was up 14.5% on a year-over-year basis. As a group, research analysts expect that Boston Scientific Co. will post 2.4 earnings per share for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.